Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 13, 2026.

The professor of neurology at Columbia University Irving Medical Center highlighted the decades of research collaboration for patients with neuromuscular disease at the 2026 MDA conference.

The study design of the phase 3 STELLAR trials, presented at the 2026 MDA Conference, aims to investigate salanersen among presymptomatic infants with spinal muscular atrophy.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 6, 2026.

Neuro-oncology experts examined how emerging cancer therapies may reshape the spectrum of paraneoplastic neurologic syndromes. [WATCH TIME: 4 minutes]

Catch up on any of the neurology headlines you may have missed in February 2026, compiled into 1 place by the NeurologyLive® team.

A new study showed that higher baseline Epworth Sleepiness Scale scores were associated with greater early continuous positive airway pressure adherence in patients with obstructive sleep apnea.

Neuro-oncology experts discussed best practices for initiating immunomodulatory therapy in patients with PNS, factors influencing neurologic recovery, and the role of early specialty involvement and supportive care in optimizing long-term outcomes. [WATCH TIME: 4 minutes]

Full data from the FENhance studies of fenebrutinib will be presented at the 2026 American Academy of Neurology Annual Meeting and submitted for regulatory review along with FENtrepid data in multiple sclerosis.

Neuro-oncology experts examined how cumulative neurotoxicity from cytotoxic and targeted therapies can obscure paraneoplastic neurologic syndromes, and how treatment timing and modification decisions influence neurologic outcomes. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Global site reactivation for the MAGNITUDE-2 trial of nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy is underway, with enrollment completion expected in the second half of 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

Neuro-oncology experts discussed how to differentiate classic PNS from immune-related neurologic adverse events, including the impact of prior immunotherapy exposure and the challenge of balancing neurologic stabilization with ongoing cancer treatment. [WATCH TIME: 5 minutes]

Neuro-oncology experts outlined screening strategies, antibody testing, and patient factors that help distinguish paraneoplastic neurologic syndromes from treatment toxicity and immune-related events. [WATCH TIME: 6 minutes]

A duo of neuro-oncologists from Northwestern Medicine discussed how paraneoplastic neurologic syndromes differ from other cancer-related neurologic complications, highlighting key diagnostic challenges.

A duo of neuro-oncologists from Northwestern Medicine explained how to distinguish paraneoplastic neurologic syndromes from treatment toxicity and metastatic disease. [WATCH TIME: 8 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The head of the Phase I Clinical Research Unit at Beijing Tiantan Hospital discussed positive clinical trial findings for a dual-target neuroprotectant in patients with acute ischemic stroke presented at ISC 2026. [WATCH TIME: 3 minutes]

The professor of medicine at McMaster University discussed findings from OCEANIC-STROKE, where treatment with asundexian reduced the risk of recurrent stroke without increasing major hemorrhage in patients. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 20, 2026.

New data suggest that prophylactic treatment with anti-calcitonin gene-related peptide monoclonal antibodies may be associated with improvements in sleep quality and daytime sleepiness among patients with migraine.

A movement disorder specialist at Northwestern Medicine discussed developments in disease-modifying research, adaptive clinical trial designs, and evolving device-based therapies in Parkinson disease. [WATCH TIME: 5 minutes]

The FDA expands pitolisant, marketed as Wakix, to treat cataplexy in pediatric patients 6 years and older with narcolepsy, making pitolisant the only nonscheduled option for excessive daytime sleepiness and cataplexy attacks.

Neurology experts highlighted ongoing developments in artificial intelligence applications, disease-modifying mechanisms, and genetic therapies expected to undergo evaluation. [WATCH TIME: 9 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 13, 2026.

The professor of neurology at the University of Alabama at Birmingham talked about findings from a CREST-2 substudy presented at ISC 2026 showing that revascularization did not improve cognitive outcomes in patients with asymptomatic carotid artery disease. [WATCH TIME: 5 minutes]

A duo of experts at ISC 2026 discussed results from a clinical trial of high-dose, home-based constraint-induced movement therapy in infants with perinatal arterial ischemic stroke. [WATCH TIME: 5 minutes]